{"Clinical Trial ID": "NCT00323479", "Intervention": ["INTERVENTION 1:", "Anastrozole 1 mg", "Anastrozole 1 mg once daily"], "Eligibility": ["Incorporation criteria:", "Postmenopausal with breast cancer and intended for adjuvant treatment with anastrozole", "WHO: performance status 0, 1 or 2", "Provision of informed written consent", "- Exclusion criteria:", "Recurrence of breast cancer, inflammatory rheumatism", "Treatment with chondromodulator, oral glucocorticoid, aromatase inhibitor, anti-estrogen, Herceptin", "Insulin-treated diabetes mellitus", "Severe renal or hepatic disorders", "\u2022 Known hypersensitivity to anastrozole"], "Results": ["Performance measures:", "Number of participants with new Arthralgia events", "[Unspecified]", "Time limit: 12 months", "Results 1:", "Title of arm/group: Anastrozole 1 mg", "Description of the arm/group: Anastrozole 1 mg once daily", "Total number of participants analysed: 106", "Type of measurement: Number", "Unit of measure: Participants 37"], "Adverse Events": ["Undesirable Events 1:", "Total: 6/110 (5.45 per cent)", "Unexplained sudden death 1/110 (0.91%)", "General pain 1/110 (0.91%)", "- Lymphangitis 1/110 (0.91%)", "- Femur fracture 1/110 (0.91%)", "Parathyroid adenoma 1/110 (0.91%)", "- Depression worsened 1/110 (0.91%)", "Calculation of bladder 1/110 (0.91%)", "Pneumopathy 1/110 (0.91%)"]}